Drug-Induced Oxidative Stress in Neurotoxicity

1. The Oxidative Stress Framework in the Nervous System

Fig. 92.1B - Interconnected pathways of neuronal injury: ROS from mitochondrial dysfunction, excitotoxic NMDA receptor activation → Ca²⁺ influx → further ROS, BBB disruption, reactive microglia/astrocytes, and impaired autophagy/UPS systems. (Bradley and Daroff's Neurology in Clinical Practice)

2. Core Molecular Mechanisms

2a. Mitochondrial Dysfunction → ROS Generation

• Heavy metals (manganese, lead, arsenic)
• Certain chemotherapy agents
• Drugs of abuse (methamphetamine, alcohol)

2b. Excitotoxicity and Calcium-Mediated ROS

2c. Dopamine Auto-oxidation

• H₂O₂ (hydrogen peroxide)
• Superoxide radicals
• Dopamine-quinones (highly reactive, directly toxic to mitochondria and proteins)

3. Drug-Specific Mechanisms

3a. Methamphetamine and Stimulants

1. Massive dopamine release from vesicular stores → dopamine auto-oxidation → H₂O₂ and superoxide formation
2. Free radical production - highly reactive peroxides and ROS directly damage dopaminergic and serotonergic terminals
3. Excitotoxicity - excess glutamate activity → NMDA receptor overactivation → Ca²⁺ influx → ROS amplification
4. Neuroinflammation - activation of astrocytes and microglia → cytokine storm (TNF-α, IL-1β, IL-6) → further ROS generation
5. Hyperthermia - methamphetamine-induced hyperthermia amplifies all oxidative processes

3b. Alcohol (Ethanol)

• Direct oxidative stress via ethanol metabolism (CYP2E1 pathway generates ROS)
• Glutamate excitotoxicity - chronic alcohol suppresses NMDA receptors; upon withdrawal, rebound NMDA hyperactivity floods neurons with Ca²⁺ and ROS
• Combined with thiamine (B1) deficiency in alcoholics → Wernicke-Korsakoff syndrome (though the direct toxic oxidative effect is distinct from nutritional deficiency)

3c. Manganese (Mn)

• Accumulates in the globus pallidus and striatum (unlike Parkinson disease, which targets substantia nigra)
• Mn²⁺/Mn³⁺ redox cycling generates ROS via Fenton-like reactions
• Disrupts GABAergic and glutamatergic neurotransmitter synthesis and metabolism
• Impairs mitochondrial function in dopaminergic neurons

3d. Lead (Pb)

• Oxidative stress (possibly via impaired antioxidant enzyme activity and direct mitochondrial damage)
• Disruption of calcium-dependent cell signaling (Pb²⁺ substitutes for Ca²⁺)
• Inhibition of nitric oxide synthase
• Altered glutamatergic signaling (inhibits NMDA receptors, disrupting synaptic plasticity)

3e. Chemotherapy Agents

• Vinca alkaloids (vincristine, vinblastine) → axonal degeneration → "stocking-glove" sensorimotor neuropathy with pain, loss of DTRs
• Cisplatin → sensorimotor neuropathy and ototoxicity (especially >400 mg/m²), partly via ROS-mediated cochlear hair cell damage
• Antibody-drug conjugates (ADCs) (e.g., brentuximab vedotin) → significant central and peripheral neurotoxicity, dose-dependent
• "Chemo brain" (chemotherapy-related cognitive impairment) - occurs in ~35% of cancer survivors; mechanisms include neurodegeneration, immune dysregulation, cytokine production, and oxidative stress gene polymorphisms

3f. HIV Antiretroviral Drugs + HIV Itself

• HIV-1 proteins gp120 and Tat trigger macrophages and microglia to release neurotoxins
• Monocyte-derived neurotoxic factors kill neurons via NMDA receptor activation and induction of oxidative stress
• Cytokines (TNF-α, IL-1, IL-6) amplify ROS production
• gp120 elevates intracellular Ca²⁺ and reduces neurotrophic factor levels
• Certain antiretroviral drugs (particularly older NRTIs) carry their own neurotoxic potential

4. Convergent Downstream Pathways

5. Antioxidant Defense Systems and Their Pharmacological Failure

• N-acetylcysteine (GSH precursor)
• Vitamin E / Vitamin C supplementation
• Selenium-dependent glutathione peroxidase support

6. Recent Evidence (PubMed, 2025)

Summary Table: Drug-Induced Oxidative Stress in Neurotoxicity

• Bradley and Daroff's Neurology in Clinical Practice - Mechanisms of Cell Loss, Lead
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Stimulant Use Disorders, Neurotoxicity
• Goldman-Cecil Medicine - Alcohol Dementia; Manganese Parkinsonism
• Tietz Textbook of Laboratory Medicine, 7th Ed. - Manganese Toxicokinetics
• Harrison's Principles of Internal Medicine 22E (2025) - Chemotherapy Neurologic Dysfunction; HIV Neuropathogenesis
• Ganong's Review of Medical Physiology - SOD and free radicals in neurodegeneration

Recent PubMed Papers: Novel Biomarkers for Drug-Induced Oxidative Neuronal Injury

Category 1: Structural Neuroaxonal Biomarkers (Blood/CSF)

NfL, NSE, Tau, and GFAP for Compound-Induced NS Injury (2023)

• Neurofilament light chain (NfL) was the top performer for detecting both CNS and PNS injury in plasma (AUC 0.97-0.99) - the highest sensitivity and specificity of all markers tested
• Tau in CSF correlated best with CNS injury (AUC 0.97) but not PNS
• NSE and GFAP were suitable for CNS injury monitoring but with lesser sensitivity than NfL
• Combining NfL (plasma) + Tau/NSE (CSF) allows localization of injury to CNS vs. PNS
• Results support cross-species translation for clinical drug safety monitoring

NfL for Chemotherapy-Induced Peripheral Neurotoxicity (2025)

• Plasma NfL was the most sensitive indicator of PNS toxicity, specifically detecting moderate dorsal root ganglion (DRG) degeneration - even when histopathology was minimal
• NF-H (neurofilament heavy chain), Tau, NSE, VEGFA, and GFAP were also measured; none matched NfL's sensitivity for peripheral injury
• A combined functional assessment + NfL biomarker approach outperformed histopathology alone
• Recommends NfL as the go-to biomarker for chemotherapy-induced peripheral neuropathy (CIPN) monitoring

NfL and GFAP for ICI-Induced Neurologic irAEs (2025)

• NfL was significantly elevated in peripheral neurologic irAEs (PNirAEs) vs. neuromuscular irAEs - making it a subtype differentiator
• GFAP was highest in CNS irAEs (CNSirAEs) - reflecting astrocytic injury specifically in central lesions
• Both markers correlated with symptom severity (CTCAE grading) and NfL elevation predicted worse outcomes (p = 0.0199)
• Tested using ultrasensitive Simoa (Single Molecule Array) technology - enabling detection at pg/mL concentrations

NfL and GFAP in Isolated Limb Perfusion (2024)

• NfL and Tau were significantly elevated in the treated extremity versus systemic circulation at the end of ILP (NfL: 17 vs 6 ng/L, p < 0.01)
• Systemic NfL and GFAP remained elevated at day 3 and day 30 post-ILP
• Simoa technology was essential for detection at this sensitivity level
• No significant correlation with regional clinical toxicity grading - suggesting subclinical injury that conventional grading misses

Category 2: Oxidative Stress-Specific Biomarkers (Tissue/Immunohistochemistry)

Multi-Biomarker Oxidative Stress Panel for Cytarabine Neurotoxicity (2026)

Category 3: Heavy Metal/Environmental Neurotoxin Biomarkers

Methylmercury Neurotoxicity Biomarkers - Systematic Review (2024)

• Antioxidant enzymes (SOD, catalase, GPx) and oxidative stress markers are consistently the most sensitive to MeHg exposure in both in vitro and in vivo models
• Key biomarker categories: oxidative stress markers, neurotransmitter levels + receptor densities, synaptic proteins, proinflammatory markers (consistently overexpressed), DNA methylation (epigenetic marks)
• Proinflammatory biomarkers are uniformly elevated across all MeHg-exposed models
• Apoptotic pathway markers (caspase-3, Bax/Bcl-2 ratio) provide mechanistic confirmation

Mercury - Transcriptomics/Proteomics/Metabolomics "Omics" Biomarkers (2024)

• Transcriptomics: Gene expression changes in oxidative stress pathways (Nrf2/ARE target genes, heat shock proteins)
• Proteomics: Thiol-modified proteins, carbonylated proteins, altered cytoskeletal proteins (tubulin, neurofilaments)
• Metabolomics: Altered redox metabolites, disrupted glutathione metabolism profiles
• Emphasis on thiol/selenol-protein interactions as specific molecular signatures of mercury exposure
• Calcium homeostasis disruption as an early upstream biomarker

Organophosphate (OP) Biomarker Framework (2025)

• Beyond acetylcholinesterase (AChE): Highlights that AChE alone is insufficient as a biomarker for chronic or developmental neurotoxicity
• Non-cholinergic biomarkers prioritized:
  • Neuroinflammation markers (cytokines, GFAP)
  • Mitochondrial dysfunction markers (complex I/II activity, ATP levels)
  • Oxidative stress markers (GSH/GSSG ratio, lipid peroxidation, 8-OHdG)
  • Epigenetic modifications (DNA methylation changes in neuronal genes)
• Promotes non-invasive biomarkers (blood, urine) that correlate with behavioral and neuropathological outcomes
• Proposes a regulatory-grade biomarker ranking framework

Long-term Toxic Oil Syndrome - Blood Biomarkers Decades Later (2025)

• NfL was slightly elevated in TOS patients (p = 0.025); no significant differences in pTau217 or GFAP
• Age was the strongest predictor of all biomarker levels (especially GFAP and pTau217)
• Female sex independently associated with higher GFAP
• Suggests current blood biomarker panels may miss subtle or compartmentalized chronic neurotoxic processes
• Calls for serial biomarker assessments + oxidative stress markers + advanced neuroimaging in longitudinal studies

Summary Table: Novel Biomarkers by Type and Application

Key Themes and Future Directions

1. NfL as the leading candidate for a universal, blood-based drug-induced neuronal injury biomarker - sensitive to both CNS and PNS damage, measurable non-invasively via ultrasensitive Simoa technology
2. CNS vs. PNS distinction can be made by combining NfL (peripheral axons) + GFAP (central astrocytes) + Tau/NSE (CSF, central origin)
3. Oxidative stress-specific markers (MDA, 8-OHdG, GSH-Px, CAT, GPX4) remain important for mechanistic confirmation and tissue-level characterization, though less suited for non-invasive monitoring
4. Multi-omics approaches (transcriptomics + proteomics + metabolomics) are emerging as powerful discovery tools, especially for identifying drug-specific molecular fingerprints (e.g., thiol-modified proteins for mercury)
5. Epigenetic biomarkers (DNA methylation at neuronal gene loci) offer a window into delayed and developmental neurotoxicity that acute-phase markers may miss
6. Regulatory-grade standardization of biomarker frameworks (as proposed for OPs) is an active area - bridging preclinical animal data to clinical trial safety monitoring

Clinical Protocols Using Oxidative Neuronal Injury Biomarkers in Ongoing Drug Trials

1. Phase 1 First-in-Human Trials - Establishing Reference Thresholds

Serum NfL as a Safety Sentinel in Phase 1 (2025)

• Cohort: 270 normal healthy volunteers (NHVs) in Phase 1 trials (cross-sectional) + 80 NHVs with longitudinal sampling over 2-4 weeks
• Key protocol output: NfL 1.64-fold change from baseline = the ULN threshold for detecting drug-induced nervous system (NS) injury in Phase 1 settings
• NfL and GFAP showed age-dependence (must be age-adjusted); Tau was age-independent but ~1/3 of samples fell below the lower limit of quantification (LLOQ)
• UCH-L1 (another candidate marker) was mostly undetectable at serum levels - not recommended for Phase 1 use
• Technology used: Quanterix SIMOA (Single Molecule Array) ultrasensitive immunoassay

2. CAR-T Cell Therapy Trials - ICANS Monitoring (Most Active Area)

NfL as Pre-Treatment Risk Stratification Tool for ICANS (2024)

• 28% developed ICANS of any grade; 15.3% grade 2-4
• NfL >75 pg/mL at leukapheresis → OR 4.2 (95% CI 1.2-14.2) for grade 2-4 ICANS
• NfL >58 pg/mL at infusion → OR 4.3 (95% CI 1.3-13.7) for grade 2-4 ICANS
• CD28 domain CAR constructs (vs 4-1BB) were the strongest predictor overall, but NfL was independently significant in multivariate models

1. Guide CAR product selection (CD28 vs. 4-1BB constructs) based on individual neurotoxicity risk
2. Initiate prophylactic corticosteroid protocols for high-NfL patients
3. Flag patients for enhanced post-infusion neurological monitoring

Severity-Graded sNfL Protocol Post-CAR-T Infusion (2025)

• Baseline NfL was similarly elevated in both ICANS and non-ICANS groups (pre-existing neuroaxonal stress from prior chemo)
• Day 7 sNfL z-score ≥ 2.14 optimally differentiated moderate-severe ICANS (grade ≥2) from mild/no ICANS (p = 0.004)
• Day 7 monitoring window is the critical protocol timepoint - captures early neuroaxonal injury before clinical deterioration solidifies

GFAP + NfL + Endothelial Dysfunction Panel (2026)

• Baseline GFAP and NfL both significantly associated with ICANS development AND corticosteroid requirement
• Day 7 elevated NfL correlated with DIC, prolonged clotting time, and CRP - suggesting a systemic coagulopathy-neurotoxicity link
• GFAP elevation linked to BBB disruption; NfL to axonal injury - the two markers provide complementary, mechanistically distinct information

3. ALS (Amyotrophic Lateral Sclerosis) Trials - Pharmacodynamic Monitoring

4. Immune Checkpoint Inhibitor (ICI) Trials - neurologic irAE Monitoring

• Measure NfL + GFAP: before ICI initiation (baseline), then at each treatment cycle, and at symptom onset
• NfL elevation → peripheral neurologic irAE (PNirAE: neuropathy, radiculopathy) - prompts neurology referral + EMG/NCS workup
• GFAP elevation → CNS irAE (encephalitis, meningitis) - prompts MRI brain + LP
• Combined NfL + GFAP elevation + severity grade → predicts outcome (elevated NfL = worse prognosis at p = 0.0199)

5. AAV Gene Therapy Trials - Dorsal Root Ganglia Safety Monitoring

• Recombinant AAV gene therapy trials (rat and non-human primate models → now translating to human Phase 1)
• High-dose AAV9 and other serotypes used for spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and other neurological conditions

6. IMI NeuroDeRisk / TransBioLine Consortium Framework

• Validated NfL, GFAP, NSE, and Tau across 15 rat in vivo studies and multiple human Phase 1 cohorts
• Proposed a tiered biomarker protocol:
  1. Tier 1 (plasma NfL): First-line, non-invasive screen for any CNS/PNS injury
  2. Tier 2 (plasma GFAP + NSE): CNS-specific confirmation
  3. Tier 3 (CSF Tau): CNS injury localization and severity quantification
• This framework is being adopted by pharmaceutical companies for preclinical-to-clinical safety translation in new drug applications (NDAs/INDs)

7. Oxidative Stress Biomarkers in Trial Protocols

Summary: Where Each Biomarker is in the Trial Lifecycle